Skip to main content
Log in

3-Deazauridine (NSC 126849): an interesting modulator of biochemical response

  • Reviews
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

3-Deazauridine (NSC 126849) is a structural analog of uridine that inhibits the biosynthesis of Cytidine-5′-Triphosphate by competitive inhibition of Cytidine Triphosphate synthetase which is considered to be the primary mode of action of this nucleoside analog. Despite a paucity of clinical attention given to this drug as a single agent, it has generated much enthusiasm as a biological response modulator because of its synergistic effect with a number of antitumor agents including Cytosine Arabinoside, 5-aza-2′-deoxycytidine, 5-azacytidine, thymidine and D-galactosamine, although only the cytosine arabinoside/3-Deazauridine combination has been explored clinically. In this paper, the current status of the drug and future perspectives will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Helman LJ, Slavik M: 3-Deazauridine (NSC 126849) Clinical brochure. Investigational Drug Branch, Cancer Therapy Evaluation Progrom, Division of Cancer Treatment, National Cancer Institute, February 1976

  2. Von Hoff DD, Slavik M, Muggia FM: 5-Azacytidine — A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Int Med 85:237–245, 1976

    Google Scholar 

  3. Von Hoff DD, Slavik M: 5-Azacytidine — A new anticancer drug with significant activity in acute myeloblastic leukemia. Advances in Pharmacology and Chemotherapy 14:287–329, 1977

    Google Scholar 

  4. Slavik M: Pharmacodynamics of 6-Azauridine 2′-3′-5′ Triacetate with the special interest on new clinical indications, Ph.D. Dissertation Thesis, Czechoslovak Academy of Sciences, Prague, 1969

    Google Scholar 

  5. Welch AD, Handschumacher RE, Finch SC, Jaffe JJ, Cardoso SS, Calabresi P: A synopsis of recent investigations of 6-Azauridine (NSC-32074). Cancer Chemother Rep 9:39–46, 1960

    Google Scholar 

  6. Robins MJ, Currie BL: The synthesis of 3-Deazauridine-4-Hydroxyl-1-(NB-D-Ribopentaphosphate)-2-pyridone. Chem Comm 2:1547–1548, 1968

    Google Scholar 

  7. Bloch A, Dutschman G, Currie BL, Robins RK, Robins MJ: Preparation and biological activity of various 3-Deazapyrimidines and related nucleotides. J Med Chem 16:294–297, 1973

    Google Scholar 

  8. Wang MC, Bloch A: Studies on the mode of action of 3-Deazapyrimidines. I. Metabolism of 3-Deazauridine and 3-Deazacytidine in microbial and tumor cells. Biochem Pharmacol 21:1063–1073, 1972

    Google Scholar 

  9. Shannon WM, Arnett G, Schabel FM Jr: 3-Deazauridine: Inhibition of ribonucleic acid virus-induced cytopathogenic effects in vitro. Antimicrob Ag Chemother 2:159–163, 1972

    Google Scholar 

  10. Khare GP, Sidwell RW, Huffman JH, Tolman RL, Robins RK: Inhibition of RNA virus replication in vitro by 3-Deazacytidine and 3-Deazauridine. Proc Soc Exp Biol Med 140:880–884, 1972

    Google Scholar 

  11. Shannon WM, Brockman RW, Westbrook L, Shaddix S, Schabel FM: Inhibition of gross leukemia virus-induced plaque formation in XC cells by 3-Deazauridine. J Nat Cancer Inst 52:199–205, 1974

    Google Scholar 

  12. Brockman RW, Shaddix SC, Williams M, Nelson JA, Rose LM, Schabel FM Jr: The mechanism of action of 3-Deazauridine in tumor cells sensitive and resistant to Arabinosylcytosine. Annals New York Acad Sci 255:501–521, 1975

    Google Scholar 

  13. McPartland RP, Wang MC, Bloch A, Weinfeld H: Cytidine 5-Triphosphate Synthetase as a target for inhibition by the antitumor agent 3-Deazauridine. Cancer Res 34:3107–3111, 1974

    Google Scholar 

  14. Chabner BA, Hande KR, Drake JC: Ara-C metabolism: Implications for drug resistance and drug interactions. Bull Cancer (Paris) 66:89–92, 1979

    Google Scholar 

  15. Drake JC, Hande KR, Fuller RW, Chabner BA: Cytidine and deoxycytidylate deaminase inhibition by uridine analogs. Biochem Pharmacol 29:807–811, 1980

    Google Scholar 

  16. Belt JA, Welch AD: Transport of uridine and 6-Azauridine in human lymphoblastoid cells: Specificity for the uncharged 6-Azauridine molecule. Mol Pharm 23:153–158, 1983

    Google Scholar 

  17. Dahlig-Harley E, Paterson ARP, Robins MJ, Cass CE: Transport of uridine and 3-Deazauridine in cultured human lymphoblastoid cells. Cancer Res 44:161–165, 1984

    Google Scholar 

  18. Karle JM, Cysyk RL: 3-Deazauridine inhibition of de novo pyrimidine biosynthesis and uridine salvage in cultured L1210 cells. (Abstract) Proc Am Assoc Cancer Res 24:295, 1983

    Google Scholar 

  19. Rustum YM, Creaven PJ, Slocum HK: Biochemical and pharmacological studies of 3-Deazauridine with L1210 cells susceptible and resistant to cytosine arabinoside. In W Siegenthaler and R Luthy (eds): Current Chemotherapy. Amer Soc for Microb, Washington DC, 1978, pp 1118–1120

    Google Scholar 

  20. Cysyk RL, Gormley PE, D'Anna ME, Adamson RH: The disposition of 3-Deazauridine in mice. Drug Metab Dispos 6:125–132, 1978

    Google Scholar 

  21. Bloch A, Dutschman G, Grindey G, Simpson CL: Prevention by testosterone of the intestinal toxicity caused by the antitumor agent 3-Deazauridine. Cancer Res 34:1299–1303, 1974

    Google Scholar 

  22. NCI Investigational Drugs: Pharmaceutical Data, US Dept. of health and Human Services Public Health Service, National Institutes of health, pp 86–88, 1983

  23. Benvenuto JA, Hall SW, Farquhar D, Stewart DS, Benjamin RS, Loo TL: Pharmacokinetics and disposition of 3-Deazauridine in humans. Cancer Res 39:349–352, 1979

    Google Scholar 

  24. Creaven PJ, Priore RL, Mittelman A, Bruno S, Henderson ES, Rustum YM, Solomon JK Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-Deazauridine. Cancer Treat Rep 66:81–84, 1982

    Google Scholar 

  25. Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KB, Burgess MA, Loo TL: Penetration of 3-Deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid. Cancer Res 39:4119–4122, 1979

    Google Scholar 

  26. Yap BS, McCredie KB, Keating MJ, Bodey GP, Freireich EJ: Phase I–II study of 3-Deazauridine in adults with acute leukemia. Cancer Treat Rep 65(5–6):521–524, 1981

    Google Scholar 

  27. Rivera G, Pratt CB: Phase I study of 3-Deazauridine (NSC 126849) in children with cancer. Clin Pharm Ther 25:244–245, 1979

    Google Scholar 

  28. 3-Deazauridine Annual Report to the Food and Drug Administration, Investigational Drug Branch, NCI. April, 1982

  29. Stewart DJ, McCredie KD, Barlogie B, Valdivieso M, Benjamin RS, Burgess MA, Bodey GP: Phase I study of 3-Deazauridine in the treatment of adults with solid tumors. Cancer Treat Rep 64:1295–1299, 1980

    Google Scholar 

  30. Wiemann MC, Cummings FJ, Kaplan HG, Calabresi P: Phase I evaluation of 24-hours infusions of 3-Deazauridine (NSC 126849) in patients with solid tumors. (Abstract) Proc Am Assoc Cancer Res 21:175, 1980

    Google Scholar 

  31. Bruno S, Creaven PJ, Ledesma E, Poster D, Yoon J, Mittelman A: Phase II study of 3-Deazauridine in advanced colorectal adenocarcinoma. Am J Clin Onc 5(1):69–71, 1982

    Google Scholar 

  32. Chabner B: Pharmacologic Principles of Cancer Treatment. WB Saunders, 1982, pp 387–401

  33. Chu MY, Fischer GA: A proposed mechanism of action of 1-B-D Arabinofuranosylcytosine as an inhibitor of the growth of leukemic cells. Biochem Pharmacol 11:423–430, 1962

    Google Scholar 

  34. Muller WEG; Rational design of arabinosyl nucleosides as antitumor and antiviral agents. J Antibiot (Tokyo) 30 (Suppl): 104–120, 1977

    Google Scholar 

  35. Kufe DW, Major PP, Egan EM, Beardsley GP: Correlation of cytotoxicity with incorporation of Ara-C into DNA. J Biol Chem 255:8997–9000, 1980

    Google Scholar 

  36. Hawtrey AO, Scott-Burden T, Robertson G: Inhibition of glycoprotein and glycolipid synthesis in hamster embryo cells by Cytosine Arabinoside and Hydroxyurea. Nature 252:58–60, 1974

    Google Scholar 

  37. Mills-Yamamoto C, Lauzon GJ, Paterson ARP: Toxicity of combinations of Arabinosylcytosine and 3-Deazauridine toward neoplastic cells in culture. Biochem Pharmacol 27:181–186, 1978

    Google Scholar 

  38. Chalbot GG, Bouchard J, Momparler RL: Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-Deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 32(7):1327–1328, 1983

    Google Scholar 

  39. Lauzon GJ, Yang SE, Paterson ARP: Cell cycle arrest as a basis of enhancement of 1-B-D-arabinofuranosylcytosine anabolism in human lymphoblastoid RPMI 6410 cells cultured with Deazauridine. Biochem Pharmacol 30(14):1889–1894, 1981

    Google Scholar 

  40. Jackson RC, Williams JC, Weber G: Enzyme patterndirected chemotherapy: Synergistic interaction of 3-Deazauridine with D-galactosamine. Cancer Treat Rep 60:835–843, 1976

    Google Scholar 

  41. Campbell J, Rustum Y: Synergistic interaction between 3-Deazauridine (DAUR) and Arabinosylcytosine (Ara-C) in mice bearing L1210. (Abstract) Proc Am Assoc Cancer Res 21:277, 1980

    Google Scholar 

  42. Paterson ARP, Jakobs ES, Lauzon GJ, Weinstein WM: Drug sequence — dependent toxicity and small bowel mucosal injury in mice treated with low doses of 3-Deazauridine and 1-B-D-arabinofuranosylcytosine. Cancer Res 39:2216–2219, 1979

    Google Scholar 

  43. Bloch A, Wang MC, Simpson CL: Prevention by testosterone of the intestinal toxicity caused by antitumor agent 3-Deazauridine. (Abstract) Proc Am Assoc Cancer Res 14:97, 1973

    Google Scholar 

  44. Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCreadie K: In vivo cellular kinetics and pharmacological studies of 1-B-D-arabinofuranosylcytosine and 3-Deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 41:1227–1235, 1981

    Google Scholar 

  45. Creaven PJ, Rustum YM, Madajewicz S, Bakshi M, Karakousis C, Pontes JE, Takita H, Henderson ES, Solomon J: Initial clinical and pharmacologic studies of Cytosine Arabinoside (Ara-C) modulated by 3-Deazauridine (DAUR). (Abstract) Proc Am Soc Clin Oncol 2:30, 1983

    Google Scholar 

  46. Pliml J, Šorm F: Synthesis of 2′ deoxy-D-furanosyl-5-azacytosine. Colin Czech Chem Commun 29:2576–2578, 1964

    Google Scholar 

  47. Momparler RL, Gonzales FA: Effect of intravenous infusion of 5-Aza-2′-deoxycytidine on survival time of mice with L1210 leukemia. Cancer Res 38:2673–2678, 1978

    Google Scholar 

  48. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin Kun-Tsan, Momparler LF: Phase I study on 5-Aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res 5(6):453–462, 1981

    Google Scholar 

  49. Momparler RL, Derse D: Kinetics of phosphorylation of 5-Aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28:1443–1444, 1979

    Google Scholar 

  50. Veselý J, Čihák A, Šorm F: Association of decreased uridine and deoxycytidine kinase with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-Azacytidine and 5-Aza-2′-deoxycytidine. Cancer Res 30:2180–2186, 1970

    Google Scholar 

  51. Veselý J, Čihák A: Incorporation of a potent antileukemic agent, 5-Aza-2′-deoxycytidine, into DNA of Cells from leukemic mice. Cancer Res 37:3684–3689, 1977

    Google Scholar 

  52. Momparler RL, Veselý J, Momparler LF, Rivard GE: Synergistic action of 5-Aza-2′-deoxycytidine and 3-Deazauridine on L1210 leukemic cells and EMT 6 tumor cells. Cancer Res 39:3822–3827, 1979

    Google Scholar 

  53. Momparler RL, Wilson VL, Jones PA: Correlation of inhibition of DNA methylation by 5-Aza-2′-deoxycytidine and its antileukemic activity. Proc 13th Int Canc Congress 1793, 1982

  54. Momparler RL, Fischer GA: Mammalian deoxynucleoside kinases. I. Deoxycytidine kinsase: purification, properties and kinetic studies with Cytosine Arabinoside. J Biol Chem 243:4298–4304, 1968

    Google Scholar 

  55. Momparler RL, Goodman J: In vitro cytotoxic and biochemical effect of 5-Aza-2′-deoxycytidine. Cancer Res 37:1636–1639, 1977

    Google Scholar 

  56. Momparler RL: Pharmacology of 5-Aza-2′-deoxycytidine. In Antimetabolites in Biochemistry, Biology and Medicine J Skoda and P Langen (eds): Pergamon Press, New York, 1979, p 33

    Google Scholar 

  57. Graham FL, Whitmore GF: The effect of 1-B-D-arabinofuranosylcytosine on growth, viability and DNA synthesis of mouse L-cells. Cancer Res 30:2627–2635, 1970

    Google Scholar 

  58. Chu MY, Fischer GA: The incorporation of 3-H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem Pharmacol 17:753–767, 1968

    Google Scholar 

  59. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20:85–93, 1980

    Google Scholar 

  60. Šorm F, Pískala A, Čihák A, Veselý J: 5-Azacytidine, a new highly effective cancerostatic. Experientia 20:202–203, 1964

    Google Scholar 

  61. Haňka LJ, Evans JS, Mason DJ, Deitz A: Microbial production of 5-Azacytidine. I. Production and biological activity. Antimicrobial Agents Chemo pp 619–624, 1966

  62. Chabner B: Pharmacologic Principles of Cancer Treatment. W.B. Saunders, 1982, pp 202–212

  63. Veselý J, Čihák A, Šorm F: Biochemical mechanisms of drug resistance. IV. Development of resistance to 5-Azacytidine and simultaneous depression of pyrimidine metabolism in leukemic mice. Int J Cancer 2:639–646, 1967

    Google Scholar 

  64. Veselý J, Čihák A: 5-Azacytidine: mechanism of action and biological effects in mammalian cells. Pharm Ther 2:813–840, 1978

    Google Scholar 

  65. Grant S, Cadman E: Altered 5-Azacytidine metabolism following 3-Deazauridine treatment of L5178Y and human myeloblasts. Cancer Res 40:4000–4006, 1980

    Google Scholar 

  66. Li LH, Olin EJ, Buskirk HH, Reineke LM: Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res 30:2760–2769, 1970

    Google Scholar 

  67. Plagemann PGW, Behrens M, Abraham D: Metabolism and cytotoxicity of 5-Azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Res 38:2458–2466, 1978

    Google Scholar 

  68. Li ZR, Campbell J, Rustum YM: Effect of 3-Deazauridine on the metabolism, toxicity and antitumor activity of Azacytidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. Cancer Treat Rep 67(6):547–554, 1983

    Google Scholar 

  69. Lee T, Karon MR: Inhibition of protein synthesis in 5-Azacytidine-treated HeLa cells. Biochem Pharmacol 25:1737–1742, 1976

    Google Scholar 

  70. Kaloušek F, Raška K, Jurovik M, et al.: Effect of 5-Azacytidine on the acceptor activity of sRNA. Colln Czech Chem Commun 31:1421–1424, 1966

    Google Scholar 

  71. Čihák A, Veselý H, Šorm F: Thymidine kinase and polyribosomal distribution in regenerating rat liver following 5-Azacytidine. Biochem Biophys Acta 166:277–279, 1968

    Google Scholar 

  72. Čihák A, Veselý J: Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-Azacytidine. Biochem Pharmacol 21:3257–3265, 1972

    Google Scholar 

  73. Lee T: Modification of tRNA by 5-Azacytidine in HeLa cells (Abstract). Proc Am Assoc Cancer Res 14:94, 1973

    Google Scholar 

  74. Weiss JW, Pitot HC: Inhibition of ribosomal precursor RNA maturation by 5-Azacytidine and 8-Azaguanine in Novikoff hepatoma cells. Arch Biochem Biophys 165:588–596, 1974

    Google Scholar 

  75. Doskočil J, Šorm F: The determination of 5-Azapyrimidines and their derivatives in bacterial RNA. FEBS Lett 2:30–32, 1974

    Google Scholar 

  76. Veselý J, Čihák A, Šorm F: Biochemical mechanism of drug resistance. VII. Inhibition of orotic acid metabolism by 5-Azacytidine in leukemic mice sensitive and resistant to 5-Azacytidine. Biochem Pharmacol 17:519–524, 1968).

    Google Scholar 

  77. Čihák A: Modulation of orotate phosphoribosyltransferase and orotidine 5′-phosphate decarboxylase activities in regenerating rat liver by 5-Azacytidine. Colln Czech Chem Commun 39:3782–3792, 1974

    Google Scholar 

  78. Lee SS, Giovanella BC, Stehlin Jr JS: Selective lethal effect of thymidine on human and mouse tumor cells. Cell Physiol 92:401–406, 1977

    Google Scholar 

  79. Ellims PH: Thymidine as an anticancer agent alone or in combination: A biochemical appraisal. Cancer Chemother Pharm 10:1–6, 1982

    Google Scholar 

  80. Jackson RC: The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of Amethopterin, 5-Fluorodeoxyuridine, and 3-Deazauridine. J Biol Chem 253(20):7440–7446, 1978

    Google Scholar 

  81. Lowe JK, Grindey GB: Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells. Molecular Pharmacol 12:177–184, 1976

    Google Scholar 

  82. Lockshin A, Giovanella BC, Mendoza JT, Stehlin JS: Biochemical and cytotoxic effects of thymidine (TdR) and 3-Deazauridine (DAUR) on human melanoma cells. (Abstract) Proc Am Assoc Cancer Res 23:4, 1982

    Google Scholar 

  83. Bjursell G, Reichard P: Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese Hamster Ovary cells. J Biol Chem 248(11):3901–3909, 1973

    Google Scholar 

  84. White A, Handler P, Smith EL: Principles of Biochemistry, McGraw-Hill Book Co, 1978, 33

  85. Keppler DOR, Smith DF: Nucleotide contents of ascites hepatoma cells and their changes induced in D-galactosamine. Cancer Res 34:705–711, 1974

    Google Scholar 

  86. Keppler D, Decker K: Studies on the mechanism of galactosamine hepatitis. Accumulation of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 10:219–225, 1969

    Google Scholar 

  87. Keppler DOR, Rudigier JFM, Bischoff E, Decker KFA: The trapping of uridine phosphate by D-galactosamine, D-glucosamine, and 2-deoxy-D-galactose: A study on the mechanism of galactosamine hepatitis. Eur J Biochem 17:246–253, 1970

    Google Scholar 

  88. Decker K, Keppler D, Pausch J: The regulation of pyrimidine nucleotide level and its role in experimental hepatitis. Adv Enzyme Reg 11:205–230, 1973

    Google Scholar 

  89. Keppler DOR, Pausch J, Decker K: Selective uridine triphosphate deficiency induced by D-galactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis. J Biol Chem 249:211–216, 1974

    Google Scholar 

  90. Talley RW, O'Bryan RM, Tucker WG, Loo RV: Clinical pharmacology and anti-tumor activity of Cytosine Arabinoside. Cancer 20(5):809–816, 1967

    Google Scholar 

  91. Frei E III, Schlossman S, Israel M: New approaches to the treatment of non-hodgkin's lymphoma. Cancer Treat Rep 61(6):1209–1217, 1977

    Google Scholar 

  92. Cadman E, Farber L, Berd D, Bertino J: Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites. Canc Treat Rep 61:1109–1116, 1977

    Google Scholar 

  93. Sweet DL, Golomb HM, Ultmann JE, Miller JB, Stein RS, Lester EP, Mintz URI, Bitran JD, Streuli RA, Daly K (RN), Roth NO (RN): Cyclophosphamide, Vincristine, Methotrexate with leucovorin rescue, and Cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Int Med 92:785–790, 1980

    Google Scholar 

  94. Early AP, Preisler HD, Slocum H, Rustum YM: A pilot study of high dose 1-B-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology. Cancer Res 42:1587–1594, 1982

    Google Scholar 

  95. Takvorian T, Canellos GP: High-dose Cytosine Arabinoside (Ara-C) in advanced non-hodgkin's lymphoma and chronic myelogenous leukemia (CML). (Abstract) Proc Am Soc Clin Oncol 2:217, 1983

    Google Scholar 

  96. Ellims PH, Gan TE, Medley G: Cytidine triphosphate synthetase activity in lymphoproliferative disorders. Cancer Res 43:1432–1435, 1983

    Google Scholar 

  97. Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, Fletcher WS, Moss SE, Manthei RW: Phase II study of 5-Azacytidine in solid tumors. Cancer Treat Rep 61(1):55–58, 1977

    Google Scholar 

  98. Plagemann PGW, Behrens M, Abraham D: Metabolism and cytotoxicity of 5-Azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Res 38:2458–2466, 1978

    Google Scholar 

  99. Ahmed NK, Welch AD: Some properties of uridinecytidine kinase from a human malignant lymphoma. Cancer Res 39:3102–3106, 1979

    Google Scholar 

  100. Williams JC, Weber G, Morris HP: Increased UDP kinase activity in rat and human hepatomas. Nature (Lond) 253:567–569, 1975

    Google Scholar 

  101. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture. Cancer Res 43: 3466–3492, 1983

    Google Scholar 

  102. Kizaki H, Williams JC, Morris HP, Weber G: Increased cytidine 5′-triphosphate synthetase activity in rat and human tumors. Cancer Res 40:3921–3927, 1980

    Google Scholar 

  103. Weber G, Burt ME, Jackson RC, Prajda N, Lui MS, Takeda E: Purine and pyrimidine enzymic programs and nucleotide pattern in sarcoma. Cancer Res 43:1019–1023, 1983

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moriconi, W.J., Slavik, M. & Taylor, S. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. Invest New Drugs 4, 67–84 (1986). https://doi.org/10.1007/BF00172020

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172020

Key words

Navigation